Skip to content
Therapy But Better – Lifestyle
Author:
Rezera Inc.
Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026
September 23, 2026
Rezera Announces Plans to Launch the REVEAL-PAD Multi-Center Study Investigating the Role of Inflammation in Patients with Peripheral Artery Disease
September 16, 2026
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
September 9, 2026
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
September 9, 2026